GLX Analytix
1 known investors
GLX Analytix develops a blood test platform that measures glycocalyx fragments and uses AI/ML to create disease-specific biomarker signatures for diagnosing and monitoring brain diseases including neuropsychiatric, neurodegenerative, and autoimmune conditions. The company targets clinicians and healthcare providers seeking early detection and precision medicine insights for conditions like Parkinson's, multiple sclerosis, schizophrenia, and stroke.
AI & Machine LearningDigital HealthMedical Devices
Founders & leadership
B
BrianFounder & CEO
Investors · 1
In the news
- GLX Analytix Announces Strategic Investment from Labcorp Venture Fund and Alzheimer’s Drug Discovery Foundation (ADDF)einpresswire.com · 2024
- GLX Analytix Pioneering Integrating AI with New Biomarkers for Personalized Healthcare Adds Health Tech Experts to Boardeinpresswire.com · 2024
- GLX Analytix - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2023
- Danish Startup GLX Analytix Prepares for Commercialization With Seed Investment | 360Dx360dx.com · 2022
- GLX Analytix Receives Funds from DigitalDx Ventures, Vaekstfonden & CBC Investment Group to Accelerate Growtheinpresswire.com · 2022